WAVE LIFE SCIENCES LTD

WVE18 Jan 2025
Healthcare
$11.39
-0.03 (-2.83%)
Lowest Today
$10.96
Highest Today
$11.46
Today’s Open
$11.39
Prev. Close
$11.31
52 Week High
$16.74
52 Week Low
$3.5
To Invest in WAVE LIFE SCIENCES LTD

WAVE LIFE SCIENCES LTD

Healthcare
WVE18 Jan 2025
-0.03 (-2.83%)
1M
3M
6M
1Y
5Y
Low
$10.96
Day’s Range
High
$11.46
10.96
52 Week Low
$3.5
52-Week Range
52 Week High
$16.74
3.5
1 Day
-
1 Week
-2.87%
1 month return
-16.15%
3 month return
-28.4%
6 month return
+91.2%
1 Year return
+131.05%
3 Years return
+339%
5 Years return
+36.84%
10 Years return
-
Institutional Holdings
RA Capital Management, LLC
11.93
Maverick Capital Ltd
6.59
Adage Capital Partners Gp LLC
6.36
BlackRock Inc
4.79
M28 Capital Management LP
4.04
Driehaus Capital Management LLC
3.84
Siren, L.L.C.
3.75

Market Status

Fundamentals
Market Cap
1725 mln
PB Ratio
12.18
PE Ratio
0
Enterprise Value
1441.22 mln
Total Assets
274.95 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Organisation
WAVE LIFE SCIENCES LTD
Employees
266
Industry
Biotechnology
CEO
Dr. Paul B.  Bolno M.B.A., M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step